Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Palisade Bio’s regulatory paperwork is not for the faint-hearted. The company’s 10-K packs dense discussions about cash runway, clinical-trial risk and intestinal-barrier science, while each 8-K can shift sentiment overnight. If you’ve ever wondered “where can I find Palisade Bio’s quarterly earnings report 10-Q filing?� or tried to follow a sudden share offer buried in an S-1, you know the challenge. Stock Titan’s AI-powered analysis puts those worries to rest.
Our AI summaries deliver Palisade Bio SEC filings explained simply. See R&D spend trends in the latest Palisade Bio quarterly earnings report 10-Q filing, catch every Palisade Bio 8-K material events explained, and monitor Palisade Bio insider trading Form 4 transactions in real time. Whether you need the Palisade Bio annual report 10-K simplified or Palisade Bio proxy statement executive compensation details, one click reveals plain-English insights, key tables and cross-document links.
Because pipeline progress drives valuation, investors track dilution risk, milestone payments and executive incentives. Our dashboard alerts you to Palisade Bio Form 4 insider transactions real-time, flags new at-the-market offerings, and highlights how fresh trial data could affect funding needs. Stop opening dozens of PDFs�understanding Palisade Bio SEC documents with AI means you get answers faster: Is management buying or selling? How long does cash last? What happens if the Phase 2 readout slips? Stock Titan delivers the Palisade Bio earnings report filing analysis you need—faster than the market.
Fragment from Palisade Bio, Inc.'s definitive proxy (DEF 14A) lists beneficial ownership counts for named individuals. The excerpt shows Donald Williams with 7,178 shares, Binxian Wei with 4,115 shares, J.D. Finley with 34,351 shares, Mitchell Jones, M.D., Ph.D., with 13,307 shares, and a total line showing 58,951 (context truncated). The table fragment also indicates that an asterisk denotes holdings that represent less than one percent. Several entries (Emil Chuang and others) show a dash or are otherwise not quantified in this excerpt. This content is a partial ownership table and does not provide broader narrative, percentages relative to outstanding shares, or transaction details.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 478,945 shares of Palisade Bio, Inc. The filing states the Reporting Persons share voting and dispositive power over these shares, representing 4.99% of the outstanding common stock. Armistice Capital is disclosed as the investment manager of the direct holder, the Master Fund, and Steven Boyd is identified as the managing member of Armistice Capital. The Master Fund is described as the direct holder but disclaims beneficial ownership due to its investment management agreement with Armistice Capital. The filing affirms the holdings were acquired in the ordinary course of business and not for the purpose of changing control.
Palisade Bio, Inc. reported interim results showing clinical progress on its lead candidate, PALI-2108, while facing tightened liquidity. The company completed dosing of 89 subjects across SAD, MAD, FE and a UC cohort in its Phase 1 study and announced positive results for the SAD/MAD/FE cohorts on May 27, 2025 and for the UC cohort on August 7, 2025. Management plans a Phase 1b cohort for fibrostenotic Crohn's disease and intends Phase 2 programs; an IND for the U.S. is anticipated in the first half of 2026.
Financially, Palisade had $5.4 million in cash and equivalents as of June 30, 2025, an accumulated deficit of $141.0 million, and recognized a net loss of $2.78 million for the quarter and $5.01 million for the six months ended June 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern for one year without additional financing. Subsequent to quarter-end, a July 2025 warrant inducement closed, generating approximately $3.9 million gross proceeds.
FAQ
What is the current stock price of Palisade Bio (PALI)?
What is the market cap of Palisade Bio (PALI)?
